Invention Grant
- Patent Title: Antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2
-
Application No.: US18171216Application Date: 2023-02-17
-
Publication No.: US12030927B2Publication Date: 2024-07-09
- Inventor: Juthathip Mongkolsapaya , Gavin Screaton
- Applicant: RQ BIOTECHNOLOGY LIMITED
- Applicant Address: GB London
- Assignee: RQ Biotechnology Limited
- Current Assignee: RQ Biotechnology Limited
- Current Assignee Address: GB London
- Agency: Sterne, Kessler, Goldstein & Fox P.L.L.C.
- Priority: GB 02232 2022.02.18 GB 03423 2022.03.11 GB 06777 2022.05.09 GB 12470 2022.08.26 GB 14036 2022.09.26 GB 15418 2022.10.18 GB 01959 2023.02.10
- Main IPC: C07K16/10
- IPC: C07K16/10 ; A61P31/14 ; A61K39/00
Abstract:
The invention relates to antibodies useful for the prevention, treatment and/or diagnosis of coronavirus infections, and diseases and/or complications associated with coronavirus infections, including COVID-19. In particular, the invention relates to antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2 and uses thereof.
Public/Granted literature
- US20230265170A1 ANTIBODIES Public/Granted day:2023-08-24
Information query
